E2 ModeratePreliminaryPEM unclearCross-SectionalPeer-reviewedMachine draft
[Incidence and clinical relevance of antibodies to phospholipids, serotonin and ganglioside in patients with sudden deafness and progressive inner ear hearing loss].
Heller, U, Becker, E W, Zenner, H P et al. · HNO · 1998 · DOI
Quick Summary
This study looked at whether certain antibodies (proteins the immune system makes) are found more often in people with sudden or progressive hearing loss. Researchers found that about half of hearing loss patients had antibodies against phospholipids and about half to two-thirds had antibodies against serotonin and gangliosides. Interestingly, some patients with hearing loss also had symptoms of ME/CFS and fibromyalgia, suggesting these conditions may be connected through shared immune system abnormalities.
Why It Matters
This study identifies a potential immunological mechanism linking ME/CFS with inner ear dysfunction and hearing loss—conditions that frequently co-occur in ME/CFS patients. The findings suggest screening for specific autoantibodies may help explain multisystem symptoms in ME/CFS and could guide targeted investigation of immune-mediated pathology affecting both auditory and systemic function.
Observed Findings
- Phospholipid antibodies detected in 49% of sudden hearing loss patients and 50% of progressive hearing loss patients.
- Serotonin antibodies found in 53% of sudden hearing loss and 63% of progressive hearing loss patients.
- Ganglioside antibodies identified in 53% of sudden hearing loss and 63% of progressive hearing loss patients.
- Twenty-eight of the cohort (19%) had concurrent symptoms typical of ME/CFS or fibromyalgia including fatigue, myalgia, arthralgia, and cognitive/mood symptoms.
Inferred Conclusions
- Autoantibodies against phospholipids, serotonin, and gangliosides are frequently present in patients with inner ear hearing loss disorders.
- Inner ear disorders may share immunological mechanisms with ME/CFS and fibromyalgia syndrome.
- These three autoantibodies may play an etiological role in hearing loss pathogenesis.
- Clinicians should screen patients with inner ear disorders for concurrent ME/CFS and fibromyalgia symptoms and test for these antibodies when such overlap is present.
Remaining Questions
- Do these antibodies directly cause hearing loss or are they epiphenomena of broader immune dysfunction?
- What is the temporal relationship between autoantibody development and symptom onset in hearing loss versus ME/CFS?
What This Study Does Not Prove
This study does not prove these antibodies cause hearing loss or ME/CFS—only that they are present together. The cross-sectional design cannot establish causality or temporal relationships. The study lacks healthy controls and patients with hearing loss alone (without systemic symptoms), so it cannot determine whether these antibodies are specific to the hearing loss, the ME/CFS/fibromyalgia overlap, or simply markers of immune activation in general.
Tags
Symptom:PainFatigue
Biomarker:Autoantibodies
Method Flag:Weak Case DefinitionSmall SampleExploratory OnlyMixed Cohort
Metadata
- DOI
- 10.1007/s001060050275
- PMID
- 9677490
- Review status
- Machine draft
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →